Logo image of PNT

POINT BIOPHARMA GLOBAL INC (PNT) Stock Fundamental Analysis

USA - NASDAQ:PNT - US7305411099 - Common Stock

12.5 USD
+0.02 (+0.16%)
Last: 12/26/2023, 8:10:43 PM
12.51 USD
+0.01 (+0.08%)
After Hours: 12/26/2023, 8:10:43 PM
Fundamental Rating

5

Taking everything into account, PNT scores 5 out of 10 in our fundamental rating. PNT was compared to 534 industry peers in the Biotechnology industry. PNT has an excellent financial health rating, but there are some minor concerns on its profitability. PNT has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

PNT had positive earnings in the past year.
In the past year PNT had a positive cash flow from operations.
PNT Yearly Net Income VS EBIT VS OCF VS FCFPNT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 0 50M -50M 100M 150M

1.2 Ratios

PNT's Return On Assets of 20.22% is amongst the best of the industry. PNT outperforms 99.49% of its industry peers.
PNT has a better Return On Equity (22.77%) than 97.81% of its industry peers.
With an excellent Return On Invested Capital value of 18.63%, PNT belongs to the best of the industry, outperforming 99.33% of the companies in the same industry.
Industry RankSector Rank
ROA 20.22%
ROE 22.77%
ROIC 18.63%
ROA(3y)-20.26%
ROA(5y)N/A
ROE(3y)-32.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PNT Yearly ROA, ROE, ROICPNT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 20 -20 -40 -60 -80

1.3 Margins

Looking at the Profit Margin, with a value of 39.62%, PNT belongs to the top of the industry, outperforming 99.33% of the companies in the same industry.
PNT has a Operating Margin of 44.22%. This is amongst the best in the industry. PNT outperforms 98.99% of its industry peers.
Industry RankSector Rank
OM 44.22%
PM (TTM) 39.62%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PNT Yearly Profit, Operating, Gross MarginsPNT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 10 20 30 40 50

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PNT is creating some value.
PNT has more shares outstanding than it did 1 year ago.
PNT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PNT Yearly Shares OutstandingPNT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 20M 40M 60M 80M 100M
PNT Yearly Total Debt VS Total AssetsPNT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

PNT has an Altman-Z score of 16.90. This indicates that PNT is financially healthy and has little risk of bankruptcy at the moment.
PNT has a Altman-Z score of 16.90. This is amongst the best in the industry. PNT outperforms 91.23% of its industry peers.
The Debt to FCF ratio of PNT is 0.06, which is an excellent value as it means it would take PNT, only 0.06 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.06, PNT belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that PNT is not too dependend on debt financing.
PNT has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.06
Altman-Z 16.9
ROIC/WACC1.67
WACC11.15%
PNT Yearly LT Debt VS Equity VS FCFPNT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 100M 200M 300M 400M

2.3 Liquidity

PNT has a Current Ratio of 9.13. This indicates that PNT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PNT (9.13) is better than 73.52% of its industry peers.
A Quick Ratio of 9.13 indicates that PNT has no problem at all paying its short term obligations.
PNT has a Quick ratio of 9.13. This is in the better half of the industry: PNT outperforms 73.69% of its industry peers.
Industry RankSector Rank
Current Ratio 9.13
Quick Ratio 9.13
PNT Yearly Current Assets VS Current LiabilitesPNT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

PNT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 195.40%, which is quite impressive.
EPS 1Y (TTM)195.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PNT will show a very strong growth in Earnings Per Share. The EPS will grow by 22.94% on average per year.
PNT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 72.58% yearly.
EPS Next Y9.21%
EPS Next 2Y-2.62%
EPS Next 3Y36.93%
EPS Next 5Y22.94%
Revenue Next Year-14.35%
Revenue Next 2Y21.4%
Revenue Next 3Y112.36%
Revenue Next 5Y72.58%

3.3 Evolution

PNT Yearly Revenue VS EstimatesPNT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
PNT Yearly EPS VS EstimatesPNT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 -1 1.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 15.06 indicates a correct valuation of PNT.
97.47% of the companies in the same industry are more expensive than PNT, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.77, PNT is valued a bit cheaper.
PNT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 15.06
Fwd PE N/A
PNT Price Earnings VS Forward Price EarningsPNT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PNT is valued cheaper than 97.98% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PNT is valued cheaply inside the industry as 97.64% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 14.37
EV/EBITDA 6.16
PNT Per share dataPNT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PNT's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PNT's earnings are expected to grow with 36.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.64
PEG (5Y)N/A
EPS Next 2Y-2.62%
EPS Next 3Y36.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PNT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

POINT BIOPHARMA GLOBAL INC

NASDAQ:PNT (12/26/2023, 8:10:43 PM)

After market: 12.51 +0.01 (+0.08%)

12.5

+0.02 (+0.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2023-11-13/bmo
Earnings (Next)03-22 2024-03-22/amc
Inst Owners0.74%
Inst Owner Change0%
Ins Owners5.11%
Ins Owner Change0%
Market Cap1.33B
Analysts69.33
Price Target15.05 (20.4%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.81%
Min EPS beat(2)19.08%
Max EPS beat(2)24.55%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)312.79%
Min Revenue beat(2)211.88%
Max Revenue beat(2)413.69%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.94%
EPS NY rev (1m)0%
EPS NY rev (3m)12.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)83.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)25.31%
Valuation
Industry RankSector Rank
PE 15.06
Fwd PE N/A
P/S 5.46
P/FCF 14.37
P/OCF 11.89
P/B 3.14
P/tB 3.14
EV/EBITDA 6.16
EPS(TTM)0.83
EY6.64%
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)0.87
FCFY6.96%
OCF(TTM)1.05
OCFY8.41%
SpS2.29
BVpS3.98
TBVpS3.98
PEG (NY)1.64
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 20.22%
ROE 22.77%
ROCE 24.56%
ROIC 18.63%
ROICexc 81.93%
ROICexgc 81.93%
OM 44.22%
PM (TTM) 39.62%
GM N/A
FCFM 38.02%
ROA(3y)-20.26%
ROA(5y)N/A
ROE(3y)-32.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.06
Debt/EBITDA 0.04
Cap/Depr 742.31%
Cap/Sales 7.92%
Interest Coverage 250
Cash Conversion 101.45%
Profit Quality 95.96%
Current Ratio 9.13
Quick Ratio 9.13
Altman-Z 16.9
F-Score6
WACC11.15%
ROIC/WACC1.67
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)195.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.54%
EPS Next Y9.21%
EPS Next 2Y-2.62%
EPS Next 3Y36.93%
EPS Next 5Y22.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-14.35%
Revenue Next 2Y21.4%
Revenue Next 3Y112.36%
Revenue Next 5Y72.58%
EBIT growth 1Y234.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.05%
EBIT Next 3Y38.92%
EBIT Next 5Y-10.32%
FCF growth 1Y261.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y371.58%
OCF growth 3YN/A
OCF growth 5YN/A